报价延迟最少15分钟:2026/04/15 09:42 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.7362 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.59/-0.48
|
|
企业价值
168.17M
|
| 资产负债 |
|
每股账面净值
0.57
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease. |
